TEVA - Teva Pharma Industries Ltd ADR logo

Teva Pharma Industries Ltd ADR

TEVA

Teva Pharmaceutical Industries develops, manufactures, and markets generic and specialty medicines, including treatments for CNS disorders, respiratory issues, and oncology. It offers a range of dosage forms and provides active pharmaceutical ingredients and contract services.

⚕️ Healthcare NYSE Listed 1990 $ USD
$1,000 invested 30 years ago →$11,982today

Score Overview

1 Year
Score
Net Growth-64.11%
Net TrendShrank
Net Income Consistency—
Rev Growth-0.16%
Rev TrendShrank
Revenue Consistency—
5 Years
Score4.3
Net Growth21.34%
Net Trend40%
Net Income Consistency—
Rev Growth8.51%
Rev Trend60%
Revenue Consistency—
10 Years
Score
Net Growth53.80%
Net Trend50%
Net Income Consistency
Rev Growth-21.34%
Rev Trend40%
Revenue Consistency
20 Years
Score3.0
Net Growth-7.33%
Net Trend45%
Net Income Consistency
Rev Growth104.91%
Rev Trend55%
Revenue Consistency
30 Years
Score
Net Growth6x
Net Trend53%
Net Income Consistency
Rev Growth18x
Rev Trend67%
Revenue Consistency
All Time
Score
Net Growth24x
Net Trend58%
Net Income Consistency
Rev Growth52x
Rev Trend69%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Teva Pharma Industries Ltd ADR has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • TEVA

2001: 17.4% · 2021: 99.5% · free through 2021 · longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 42.62—
1 Year2025-11-17
$ 24.5973.32%
5 Years2021-11-17
$ 9.16365.28%
10 Years2016-11-17
$ 37.2814.33%
20 Years2006-11-17
$ 24.6472.96%
30 Years1996-11-15
$ 3.5611x
All Time1990-03-26
$ 0.40105x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 17.22B$ 506M$ 4.08B
2025$ 17.25B$ 1.41B$ 3.55B
2024$ 16.54B-$ 1.63B$ 3.30B
2023$ 15.84B-$ 559M$ 3.22B
2022$ 14.92B-$ 2.44B$ 2.80B
2021$ 15.87B$ 417M$ 2.16B
2020$ 16.65B-$ 3.99B$ 2.17B
2019$ 16.88B-$ 999M$ 1.97B
2018$ 18.85B-$ 2.15B$ 1.78B
2017$ 22.38B-$ 16.26B$ 963M
2016$ 21.90B$ 329M$ 988M
2015$ 19.65B$ 1.58B$ 6.94B
2014$ 20.27B$ 3.05B$ 2.22B
2013$ 20.31B$ 1.26B$ 1.03B
2012$ 20.31B$ 1.96B$ 2.87B
2011$ 18.31B$ 2.75B$ 1.09B
2010$ 16.12B$ 3.33B$ 1.28B
2009$ 13.89B$ 2.00B$ 2.24B
2008$ 11.08B$ 635M$ 1.90B
2007$ 9.40B$ 1.95B$ 2.87B
2006$ 8.40B$ 546M$ 2.04B
2005$ 5.25B$ 1.07B$ 2.21B
2004$ 4.79B$ 331M$ 1.04B
2003$ 3.27B$ 691M$ 1.37B
2002$ 2.51B$ 410M$ 1.04B
2001$ 2.07B$ 278M$ 790M
2000$ 1.74B$ 148M$ 424M
1999$ 1.28B$ 117M$ 94M
1998$ 1.11B$ 68M$ 49M
1997$ 1.11B$ 101M$ 58M
1996$ 953M$ 73M$ 69M
1995$ 667M$ 79M$ 73M
1994$ 587M$ 71M$ 50M
1993$ 502M$ 57M$ 39M
1992$ 406M$ 32M$ 13M
1991$ 327M$ 23M$ 7M
IPO1990$ 329M$ 20M$ 15M
TEVA - Teva Pharma Industries Ltd ADR logo

Teva Pharma Industries Ltd ADR fundamental performance

Between 2020 and 2025, revenue grew from $ 16.65B to $ 17.25B and net income went from -$ 3.99B to $ 1.41B. Revenue increased in 3 of those 5 years; net income in 2.

Across Teva Pharma Industries Ltd ADR's full reported history, from 1990 to 2025, revenue grew from $ 329M to $ 17.25B and net income grew from $ 20M to $ 1.41B. Revenue increased in 69% of the years measured; net income in 58%.

Teva Pharma Industries Ltd ADR currently holds a 20-year HDB Score of 3.0 out of 10. How the HDB Score is calculated.

Membership

Continue TEVA’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,187 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies